Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Three predominant prostatic proteins.

P A Abrahamsson1, H Lilja

  • 1Department of Urology, University of Lund, Malmö General Hospital, Sweden.

Andrologia
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Composite Functional and Quality of Life Outcomes in Adults Operated for Cloacal Malformation.

Journal of pediatric surgery·2024
Same author

The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality.

British journal of cancer·2015
Same author

miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients.

British journal of cancer·2013
Same author

Integrated acoustic immunoaffinity-capture (IAI) platform for detection of PSA from whole blood samples.

Lab on a chip·2013
Same author

Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.

Journal of internal medicine·2010

Prostate-specific antigen (PSA) is a more sensitive marker for poorly differentiated prostate cancer than prostatic acid phosphatase (PAP) or beta-microseminoprotein (beta-MSP). However, PAP and beta-MSP have limitations as cancer markers due to cross-reactivity and potential non-prostatic production.

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Background:

  • Prostatic acid phosphatase (PAP), prostate-specific antigen (PSA), and beta-microseminoprotein (beta-MSP) are key proteins secreted by the normal human prostate.
  • These proteins share identical immunohistochemical localization in the epithelium of normal and hyperplastic prostatic tissues.

Purpose of the Study:

  • To evaluate the utility of PAP, PSA, and beta-MSP as immunohistochemical markers for prostate cancer.
  • To compare the sensitivity and specificity of these markers across different grades of prostate tumors.

Main Methods:

  • Immunohistochemical analysis of PAP, PSA, and beta-MSP expression in normal, hyperplastic, and cancerous prostate tissues.
  • Correlation of marker expression levels with tumor differentiation grades (Grade I, II, III).

Related Experiment Videos

Main Results:

  • Well-differentiated (Grade I) prostate carcinomas show abundant PAP, PSA, and beta-MSP.
  • Moderately and poorly differentiated (Grade II-III) tumors exhibit reduced and more variable expression of these markers.
  • PSA demonstrated higher sensitivity as an immunohistochemical marker in poorly differentiated tumors compared to PAP and beta-MSP.

Conclusions:

  • PSA is a more reliable immunohistochemical marker for detecting poorly differentiated prostate carcinomas.
  • The diagnostic utility of PAP is limited by its structural similarity to lysosomal acid phosphatase.
  • Potential non-prostatic production may limit the use of beta-MSP as a specific marker for prostate cancer.